Rapid and sustained response of stubborn guttate psoriasis to ustekinumab: A 52-week, two-center, one-arm, observational study

Ustekinumab showed significant and prolonged efficacy in treating stubborn GP patients, particularly for those patients with SDD. The CARD14: rs11652075C>T may serve as a predictor of favorable treatment response.